PegBio Co., Ltd. (HKG:2565)

Market Cap	2.16B -39.1%
Revenue (ttm)	n/a
Net Income	-231.87M
EPS	-0.61
Shares Out	391.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,872,250
Open	6.23
Previous Close	5.53
Day's Range	5.89 - 8.28
52-Week Range	4.94 - 77.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 58
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2565

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error